EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer

Md Mijanur Rahman iD, I Darren Grice iD, Glen C Ulett iD, Ming Q Wei

Journal of Immunology Research · 2024

DOI: 10.1155/2024/4312908 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, 2024. Verfasst von Md Mijanur Rahman und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Medical Sciences Griffith University, Gold Coast 4222, QLD, Australia. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Griffith University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antigenic cell fragments, pathogen‐associated molecular patterns, and other immunostimulants in bacterial lysates or extracts may induce local and systemic immune responses in specific and nonspecific paradigms. Based on current knowledge, this review aimed to determine whether bacterial lysate has comparable functions in infectious diseases and cancer treatment. In infectious diseases, including respiratory and urinary tract infections, immune system activation by bacterial lysate can identify and combat pathogens. Commercially available bacterial lysates, including OM‐85, Ismigen, Lantigen B, and LW 50020, were effective in children and adults in treating respiratory tract infections, chronic obstructive pulmonary disease, rhinitis, and rhinosinusitis with varying degrees of success. Moreover, OM‐89, Uromune, Urovac, Urivac, and ExPEC4V showed therapeutic benefits in controlling urinary tract infections in adults, especially women. Bacterial lysate‐based therapeutics are safe, well‐tolerated, and have few side effects, making them a good alternative for infectious disease management. Furthermore, a nonspecific immunomodulation by bacterial lysates may stimulate innate immunity, benefiting cancer treatment. “Coley’s vaccine” has been used to treat sarcomas, carcinomas, lymphomas, melanomas, and myelomas with varying outcomes. Later, several similar bacterial lysate‐based therapeutics have been developed to treat cancers, including bladder cancer, non‐small cell lung cancer, and myeloma; among them, BCG for in situ bladder cancer is well‐known. Proinflammatory cytokines, including IL‐1, IL‐6, IL‐12, and TNF‐ α , may activate bacterial antigen‐specific adaptive responses that could restore tumor antigen recognition and response by tumor‐specific type 1 helper cells and cytotoxic T cells; therefore, bacterial lysates are worth investigating as a vaccination adjuvants or add‐on therapies for several cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyHumansAnimalsCommunicable DiseasesCell ExtractsBacteriaAdjuvants, ImmunologicBacterial Lysates

Substanzen

Cell ExtractsAdjuvants, ImmunologicBacterial Lysates

Autor:innen und Institutionen

  • School of Pharmacy and Medical Sciences Griffith University, Gold Coast 4222, QLD, Australia.
  • Menzies Health Institute Queensland Griffith University, Gold Coast 4222, QLD, Australia.
  • Institute for Glycomics Griffith University, Gold Coast 4222, QLD, Australia.

ORCID-Profile: Md Mijanur Rahman, I Darren Grice, Glen C Ulett

Förderung

  • Griffith University

Zitieren

APA

Rahman, M. M., Grice, I. D., Ulett, G. C., & Wei, M. Q. (2024). Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer. Journal of Immunology Research. https://doi.org/10.1155/2024/4312908

Vancouver

Rahman MM, Grice ID, Ulett GC, Wei MQ. Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer. Journal of Immunology Research. 2024. doi:10.1155/2024/4312908

BibTeX
@article{Rahman2024,
  author = {Rahman, Md Mijanur and Grice, I Darren and Ulett, Glen C and Wei, Ming Q},
  title = {Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer},
  journal = {Journal of Immunology Research},
  year = {2024},
  doi = {10.1155/2024/4312908}
}
Kostenlos starten →